Anyiam O, Ardavani A, Rashid RSA, Panesar A, Idris I. How Do Glucagon-Like Peptide-1 Receptor Agonists Affect Measures of Muscle Mass in Individuals With, and Without, Type 2 Diabetes: A Systematic Review and Meta-Analysis. Obes Rev. 2025;26(7):e13916. doi:10.1111/obr.13916.
Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of Glucagon-Like Peptide-1 Receptor Agonists and Co-Agonists on Body Composition: Systematic Review and Network Meta-Analysis. Metabolism. 2025;164:156113. doi:10.1016/j.metabol.2024.156113.
Lubberding AF, Veedfald S, Achter JS, et al. Glucagon-Like Peptide-1 Increases Heart Rate by a Direct Action on the Sinus Node. Cardiovasc Res. 2024;120(12):1427-1441. doi:10.1093/cvr/cvae120.
Lorenz M, Lawson F, Owens D, et al. Differential Effects of Glucagon-Like Peptide-1 Receptor Agonists on Heart Rate. Cardiovasc Diabetol. 2017;16(1):6. doi:10.1186/s12933-016-0490-6.
Grosicki GJ, Kim J, Fielding F, et al. Heart and Health Behavior Responses to GLP-1 Receptor Agonists: A 12-Wk Study Using Wearable Technology and Causal Inference. Am J Physiol Heart Circ Physiol. 2025;328(2):H235-H241. doi:10.1152/ajpheart.00809.2024.
Avogaro A, Fadini GP. Incretins and the Cardiovascular System: Bridging Digestion With Metabolism. Lancet Diabetes Endocrinol. 2025;13(9):790-802. doi:10.1016/S2213-8587(25)00166-4.
Oi Gabi! Tem alguma referência bibliográfica para estudar melhor sobre esses mecanismos?
Oi Jessica! Seguem algumas referências:
Anyiam O, Ardavani A, Rashid RSA, Panesar A, Idris I. How Do Glucagon-Like Peptide-1 Receptor Agonists Affect Measures of Muscle Mass in Individuals With, and Without, Type 2 Diabetes: A Systematic Review and Meta-Analysis. Obes Rev. 2025;26(7):e13916. doi:10.1111/obr.13916.
Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of Glucagon-Like Peptide-1 Receptor Agonists and Co-Agonists on Body Composition: Systematic Review and Network Meta-Analysis. Metabolism. 2025;164:156113. doi:10.1016/j.metabol.2024.156113.
Lubberding AF, Veedfald S, Achter JS, et al. Glucagon-Like Peptide-1 Increases Heart Rate by a Direct Action on the Sinus Node. Cardiovasc Res. 2024;120(12):1427-1441. doi:10.1093/cvr/cvae120.
Lorenz M, Lawson F, Owens D, et al. Differential Effects of Glucagon-Like Peptide-1 Receptor Agonists on Heart Rate. Cardiovasc Diabetol. 2017;16(1):6. doi:10.1186/s12933-016-0490-6.
Grosicki GJ, Kim J, Fielding F, et al. Heart and Health Behavior Responses to GLP-1 Receptor Agonists: A 12-Wk Study Using Wearable Technology and Causal Inference. Am J Physiol Heart Circ Physiol. 2025;328(2):H235-H241. doi:10.1152/ajpheart.00809.2024.
Avogaro A, Fadini GP. Incretins and the Cardiovascular System: Bridging Digestion With Metabolism. Lancet Diabetes Endocrinol. 2025;13(9):790-802. doi:10.1016/S2213-8587(25)00166-4.